Famous Chronic Renal Disease Stages Products from Leading Factories

Introducing our latest medical breakthrough for Chronic Renal Disease Stages – the innovative treatment developed by Sinofn (Tianjin) Pharm-Tech Co., Ltd. Our company has dedicated years of research and development to create a product that can effectively manage and improve the quality of life for patients suffering from chronic renal disease, Our treatment is designed to target the specific stages of chronic renal disease, offering personalized care and support for patients at every level of their condition. Through our advanced technology and expertise in pharmaceuticals, we have developed a solution that aims to slow down the progression of the disease and alleviate symptoms, With a focus on patient well-being and long-term health outcomes, our product has undergone rigorous testing and clinical trials to ensure its safety and effectiveness. We are committed to providing healthcare professionals and patients with a reliable and trusted solution for managing chronic renal disease stages, Choose Sinofn (Tianjin) Pharm-Tech Co., Ltd. for a revolutionary approach to treating chronic renal disease stages

Hot Selling Product

All in One, Ultra Energy and protein Total Nutrient Admixture

Snow Fungus Soup With Pear/Bird’s Nest/Jujube

Ultra-High concentrated Camp Jujube Extract

OEM Supplements of PKU-Foods for age under 12month with Phenylketonuria

OEM Supplements of PKU-Foods for age over10 with Phenylketonuria

NMN (β‑Nicotinamide Mononucleotide) – ≥99% Purity NAD⁺ Precursor for Premium Formulations

Why Trust Chronic Renal Disease Stages Factories Pioneers in the Field in 2025

In 2025, as the healthcare industry increasingly focuses on specialized treatments, the significance of reliable partners in chronic renal disease support has never been greater. Our GMP-certified operation stands out as a leading OEM/ODM partner for private label supplements tailored to meet the unique needs of renal disease management. With years of experience in global contract manufacturing since 2012, we ensure that every product, including gummies, liquids, and powders, adheres to the highest quality standards. Our low minimum order quantities (MOQ) and turnkey solutions provide a seamless supply chain experience for global buyers. By collaborating with us, you are choosing a pioneer in the field who prioritizes innovation and quality to help improve patient outcomes. As the demand for effective renal disease supplements rises, working with a trusted partner allows you to effectively meet market needs while enhancing your brand's reputation. Request a quote today to discover how we can support your business in this vital sector.

Why Trust Chronic Renal Disease Stages Factories Pioneers in the Field in 2025

Stage	Description	Prevalence (%)	Treatment Options	Patient Outcomes
Stage 1	Kidney damage with normal or increased GFR	5%	Lifestyle changes, Monitoring	Good long-term outcomes
Stage 2	Mild decrease in GFR	10%	Lifestyle changes, Medications	Generally favorable
Stage 3	Moderate decrease in GFR	30%	Dietary modifications, Medications	Variable, risk of complications
Stage 4	Severe decrease in GFR	25%	Preparing for dialysis, Medications	Increased risk of complications
Stage 5	Kidney failure (End-Stage)	10%	Dialysis, Kidney transplant	Variable, dependent on treatment

Prevalence of Chronic Renal Disease by Stage in 2025

In 2025, the prevalence of chronic renal disease (CRD) stages among the general population displays significant variation. The data indicates that Stage 1 and Stage 2 represent the highest prevalence rates, accounting for 30% and 25% of the diagnosed cases, respectively. This could suggest that there is a considerable number of individuals living with mild forms of kidney dysfunction, which may remain undetected without comprehensive screening. As the stages progress to Stage 3, the prevalence drops to 20%, illustrating a transition to more severe stages of kidney disease. Stages 4 and 5, which represent advanced chronic kidney disease and end-stage renal disease, have lower prevalence rates at 15% and 10%. This distribution highlights the importance of early intervention and regular monitoring to prevent the progression of kidney disease, ultimately emphasizing the need for increased awareness and education regarding chronic renal health.